drugset / Trial / NCT02899988
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to evaluate the efficacy of the study drug mirikizumab in participants with moderate to severe plaque psoriasis.
Timeline
- Start
- 2016-09-14
- Primary completion
- 2017-06-19
- Completion
- 2019-05-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirikizumab | Monoclonal antibody | 30 mg | Subcutaneous |
| Subject | Mirikizumab | Monoclonal antibody | 100 mg | Subcutaneous |
| Subject | Mirikizumab | Monoclonal antibody | 300 mg | Subcutaneous |